Table 1.
Study protocol
| Animal | Study parameters | Pre-Monensin | Dose number
|
Study duration | Cause of study termination | |||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||||
| 1 | Dose (mg/kg) | - | 25 | 20 | 40 | 60 | - | Elective sacrifice |
| PMD (days) | - | 0 | 13 | 24 | 35 | 65 | ||
| Monensin [ng/mL] | - | - | - | - | - | - | ||
| Plasma renin activity [μg/l/hr] | 0.9 | 1.3 | 0.4 | 0.6 | 0.5 | - | ||
| CK-MB [ng/ml] | - | - | - | - | 0.6 | - | ||
| Troponin T [ng/ml] | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | - | ||
| 2 | Dose (mg/kg) | - | 80 | - | - | - | - | Sudden death from cardiac arrhythmia |
| PMD (days) | - | 0 | - | - | - | 6 | ||
| Monensin [ng/mL] | - | 7.21 | - | - | - | - | ||
| 3 | Dose (mg/kg) | - | 60 | 80 | - | - | - | Elective sacrifice |
| PMD (days) | - | 0 | 12 | - | - | 34 | ||
| Monensin [ng/mL] | - | N/A | 5.05 | - | - | - | ||
| Plasma renin activity [μg/l/hr] | 0.7 | 0.7 | 1.0 | - | - | - | ||
| CK-MB [ng/ml] | 1.3 | 1.1 | 1.0 | - | - | - | ||
| Troponin T [ng/ml] | <0.01 | <0.01 | <0.01 | - | - | - | ||
| 4 | Dose (mg/kg) | - | 60 | - | - | - | - | Severe refractory heart failure |
| PMD (days) | - | 0 | - | - | - | 4 | ||
| Monensin [ng/mL] | - | 6.75 | - | - | - | - | ||
| 5 | Dose (mg/kg) | - | 40 | - | - | - | - | Severe refractory heart failure |
| PMD (days) | - | 0 | - | - | - | 5 | ||
| Monensin [ng/mL] | - | 23.0 | - | - | - | - | ||
Monensin [ng/mL], blood concentration 1 d after each dose; PMD, post first-monensin day; CK-MB, creatine kinase-myocardial band. Plasma renin activity, CK-MB, and troponin T levels were measured pre-monensin and 7 days after each dose administration.